Efgartigimod PH20 SC

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

New Onset Generalized Myasthenia Gravis (gMG)

Conditions

New Onset Generalized Myasthenia Gravis (gMG)

Trial Timeline

Apr 17, 2025 → May 1, 2027

NCT ID

NCT06909214

About Efgartigimod PH20 SC

Efgartigimod PH20 SC is a approved stage product being developed by Argenx for New Onset Generalized Myasthenia Gravis (gMG). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06909214. Target conditions include New Onset Generalized Myasthenia Gravis (gMG).

What happened to similar drugs?

6 of 20 similar drugs in New Onset Generalized Myasthenia Gravis (gMG) were approved

Approved (6) Terminated (4) Active (11)

🔄E2007EisaiPhase 3

🔄Zonisamide + PlaceboEisaiPhase 3

🔄Perampanel + PlaceboEisaiPhase 3

❌RufinamideEisaiPhase 3

✅PerampanelEisaiApproved

🔄PerampanelEisaiPhase 3

🔄Eslicarbazepine acetate + Eslicarbazepine acetateSumitomo PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07264426	Pre-clinical	Recruiting	Aug 11, 2025	Oct 1, 2029	Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT06909214	Approved	Recruiting	Apr 17, 2025	May 1, 2027	New Onset Generalized Myasthenia Gravis (gMG)
NCT06684847	Phase 3	Recruiting	Jan 15, 2025	Jul 1, 2028	Primary Sjogrens Disease
NCT06637072	Approved	Active	Dec 10, 2024	Feb 23, 2026	Chronic Inflammatory Demyelinating Polyneuropathy
NCT06392386	Phase 2/3	Recruiting	Jun 28, 2024	Sep 30, 2026	Generalized Myasthenia Gravis
NCT05979441	Phase 3	Recruiting	Sep 12, 2023	Sep 1, 2028	Myositis
NCT04812925	Phase 3	Active	Nov 17, 2021	Oct 1, 2026	Primary Immune Thrombocytopenia
NCT04818671	Phase 3	Completed	Apr 26, 2021	Dec 31, 2024	Generalized Myasthenia Gravis
NCT04687072	Phase 3	Completed	Dec 16, 2020	Oct 9, 2023	Primary Immune Thrombocytopenia
NCT04280718	Phase 2	Active	Sep 18, 2020	Apr 30, 2027	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Competing Products

20 competing products in New Onset Generalized Myasthenia Gravis (gMG)

See all competitors

Product	Company	Stage	Hype Score
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125	Cassava Sciences	Phase 1	19
E2007	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
perampanel + perampanel	Eisai	Phase 1	29
Perampanel and Microgynon-30 + Perampanel and Microgynon-30	Eisai	Phase 1	29
Perampanel	Eisai	Pre-clinical	26
Zonisamide + Placebo	Eisai	Phase 3	40
Perampanel + Placebo	Eisai	Phase 3	40
Rufinamide	Eisai	Phase 3	32
Eslicarbazepine Acetate tablets	Eisai	Pre-clinical	26
Perampanel	Eisai	Pre-clinical	26
Perampanel	Eisai	Approved	43
Zonisamide tablets	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Eslicarbazepine acetate + Eslicarbazepine acetate	Sumitomo Pharma	Phase 3	40
BGG492	Novartis	Phase 2	35
Cyclosporine - cyclosporine microemulsion	Novartis	Approved	43
Investigational new drug, company code: BGG492 + Placebo + Investigational new drug, company code: BGG492	Novartis	Phase 2	35
Canakinumab	Novartis	Phase 3	40
Everolimus + Ranibizumab	Novartis	Phase 2	27